Trial · NCT06236061
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
NCT06236061, Phase 3, Completed, Novartis Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy. Trials, record NCT06236061. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06236061
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
- NCT number
- NCT06236061
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 718 participants, actual
- Lead sponsor
- Novartis Pharmaceuticals
- Conditions
- Hypertension
- Interventions
- LCZ, LCZ/AML 200 mg/2.5 mg, LCZ/AML 200 mg/5 mg, LCZ/AML 200 mg/10 mg, Placebo
- First posted
- 2024-02-01
- Last updated
- 2026-01-13
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | [Core Part] Change from baseline to Week 8 in msSBP | Baseline, Week 8 | Change from baseline to Week 8 in mean sitting systolic blood pressure (msSBP) |
| Secondary | [Core Part] Change from baseline to Week 8 in maSBP | Baseline, Week 8 | Change from baseline to Week 8 in mean 24-hour ambulatory systolic blood pressure (maSBP) |
| Secondary | [Core Part] Proportion of patients achieving a blood pressure control after 8 weeks of treatment | 8 weeks | Proportion of patients achieving a blood pressure control (msSBP \<140 mmHg and msDBP \<90 mmHg) after 8 weeks of treatment |
| Secondary | [Core Part] Change from baseline to Week 8 in msDBP | Baseline, Week 8 | Change from baseline to Week 8 in mean sitting diastolic blood pressure (msDBP) |
| Secondary | [Core Part] Change from baseline to Week 8 in maDBP | Baseline, Week 8 | Change from baseline to Week 8 in mean 24-hour ambulatory diastolic blood pressure (maDBP) |
| Secondary | [Core Part] Proportion of patients achieving a msSBP response after 8 weeks of treatment | 8 weeks | Proportion of patients achieving a msSBP response (\<140 mmHg or a reduction ≥20 mmHg from baseline) after 8 weeks of treatment |
| Secondary | [Core Part] Proportion of patients achieving a msDBP response after 8 weeks of treatment | 8 weeks | Proportion of patients achieving a msDBP response (\<90 mmHg or a reduction ≥10 mmHg from baseline) after 8 weeks of treatment |
| Secondary | [Core Part] Change from baseline to Week 8 in daytime, nighttime and early morning maSBP | Baseline, Week 8 | Change from baseline to Week 8 in daytime, nighttime and early morning maSBP |
| Secondary | [Core Part] Change from baseline to Week 8 in daytime, nighttime and early morning maDBP | Baseline, Week 8 | Change from baseline to Week 8 in daytime, nighttime and early morning maDBP |
| Secondary | [Core Part] Number of patients with treatment-emergent adverse events | Up to 8 weeks | Number of patients experiencing treatment-emergent adverse events including (but not limited to) any unfavorable and unintended signs, symptoms or disease, abnormal vital signs, electrocardiogram data, safety lab measurements that induce clinical signs or symptoms, are considered clinically significant or require therapy |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06236061
GET https://conductscience.org/api/trials/v1/NCT06236061/registered